Αποτελέσματα Αναζήτησης
The Agency for Healthcare Research and Quality (AHRQ) has requested a review on screening and treatment for depression, anxiety disorders, and suicide risk in adults, including pregnant people.
For KQs 1 and 3 (benefits and harms of screening), we included RCTs of primary care (or comparable broad healthcare-based) adult populations (age ≥19), including pregnant people, investigating the benefits or harms of brief screening interventions for depression, anxiety, or suicide risk.
The US Preventive Services Task Force (USPSTF) rec-ommends screening for depression in the general adult pop-ulation, including pregnant and postpartum women, and further suggests that screening should be implemented “with adequate systems in place to ensure accurate diagnosis, effec-tive treatment, and appropriate follow-up.”2 The USPSTF
This systematic review to support the 2023 US Preventive Services Task Force Recommendation Statement on depression and suicide risk screening summarizes published evidence on the benefits and harms of screening for, and treatment of, depression and suicide risk in primary care settings, including during pregnancy and postpartum.
15 Αυγ 2016 · DETECTION. The USPSTF found convincing evidence that screening improves the accurate identification of adult patients with depression in primary care settings, including pregnant and postpartum...
21 Μαΐ 2024 · Depression screening tests can be valuable, with the most widely one used being the Patient Health Questionnaire-9 (PHQ-9). It is important to understand, however, that the results obtained from...
22 Αυγ 2022 · The evidence is very uncertain about the effect of screening for depression in pregnant or postpartum women in primary care or non-mental health clinic settings. Well-conducted and better-reported trials are needed that meet the screening trial criteria used in this review.
